Sign in
Taking people in United StatesNo phase

Tests PAP breathing device in stroke patients with sleep apnea

Tests a breathing machine against usual care in adults with stroke and sleep apnea.

Key facts

Who runs it
Yale University
Where
New Haven, United StatesSee the site
Trial code
Registry title
The Recovery in Stroke Using PAP Study
Status
Recruiting
People taking part
360 people, planned
Started
1 Sept 2019
Planned end
Oct 2025
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • PAP
  • HLE
Record updated
5 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who just had an ischemic stroke and have moderate or severe obstructive sleep apnea (OSA). It compares PAP treatment with usual care.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Acute ischemic stroke confirmed by brain imaging within 48 hours of symptom onset, and within 5 days of the first neurologic symptoms. Moderate or severe OSA (obstructive apnea-hypopnea index AHI of 15 or higher).
Earlier treatment
People who used prescribed PAP for OSA in the past cannot join.
Biomarker or test result
Sleep test result: obstructive apnea-hypopnea index (AHI) of 15 or higher.

Main reasons for not taking part

  • Past use of prescribed PAP for OSA
  • A suspected sleep disorder other than OSA, such as narcolepsy
  • Life expectancy under 6 months
  • Needs mechanical ventilation
  • Cannot give their own informed consent

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Having an acute ischemic stroke with brain imaging within 48 hours of symptoms onset
  • Being within 5 days of neurologic symptoms onset
  • Moderate (15 =< overall AHI < 30) /severe (overall AHI >= 30) OSA, thus with an obstructive apnea-hypopnea index AHI >= 15

Who cannot take part

  • Inability to provide their own informed consent. To enhance the generalizability of our study, all stroke severity will be included. However, we will exclude patients who cannot provide their own consent. This is because patients will need to participate actively in the protocol with a behavioral intervention. An assessment of the patient's competence to provide consent will be made based on published recommendations
  • Suspected sleep disorder other than OSA (e.g., narcolepsy) (because such patients should be referred for a formal PSG in a sleep laboratory)
  • Past use of prescribed PAP for OSA
  • Life expectancy is less than 6 months (e.g., hospice patients)
  • Patients who require mechanical ventilation (because such patients could not participate in the intervention protocol)
  • Non-English language patients (because the intervention strategy involves forming a relationship between the patient and research staff)
  • Central sleep apnea with > 50% of respiratory events classified as central apnea
  • Resting oxygen saturation < 90%

Where in United States

  • Yale UniversityNew Haven, United StatesContact: Klar Yaggi, MDTaking people

About the trial

What the trial wants to find out

The proposed study is a randomized controlled trial among an anicipated 180 participants with acute ischemic stroke and mod/severe OSA diagnosed by ambulatory polysomnography (PSG) comparing PAP treatment with usual care concerning the primary outcome of functional recovery.

The 4 groups in the trial

  • PAP treatment- AcuteTreatment being tested

    Acute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support. All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur.

    Treatment: PAP and HLE

  • Usual Care (HLE)Existing treatment, for comparison

    All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur.

    Treatment: HLE

  • PAP treatment- SubacuteTreatment being tested

    Acute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support. All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur.

    Treatment: PAP and HLE

  • Exploratory armOther group

    Non-randomized comparison/exploratory group of subjects with ischemic stroke and Apnea-Hypopnea Index (AHI) \<15 (approximately 120 participants) and approximately 60 subjects with ICH (who do not need legally authorized representative for consent - most likely mild form of ICH) and any level of AHI.

    Treatment: HLE

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Recovery in Stroke Using PAP Study
Plain-language title
Tests PAP breathing device in stroke patients with sleep apneaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
5 September 2025